
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is strategically positioned to capitalize on the rapidly growing biosimilars market, projected to reach $100 billion by 2030, enhancing its competitive advantage in the healthcare sector. The company’s innovative strategies, including the introduction of cost-sharing options and anticipated double-digit savings in GLP-1 net costs, are expected to provide substantial financial benefits to employer clients. Furthermore, the expansion of its Evernorth segment is anticipated to bolster earnings resilience during economic downturns, reflecting Cigna's ability to navigate challenging financial landscapes effectively.
Bears say
The financial outlook for Cigna Group appears negative due to several key risks affecting its operations. These include potential challenges in accurately pricing healthcare costs, ongoing regulatory scrutiny of pharmacy benefit managers (PBMs), and slow adoption of biosimilars, which could hinder growth in its Evernorth segment. Additionally, rising unemployment may negatively impact commercial membership, and management expresses concerns about significant client attrition and the inability of employers to achieve desired outcomes under new benefit structures.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares